Praliciguat

Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO) -sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure[1][2][3].

Product Specifications

CAS Number

[1628730-49-3]

Product Name Alternative

IW-1973

UNSPSC

12352005

Target

Apoptosis; Guanylate Cyclase

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/praliciguat.html

Purity

99.35

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NCC(C(F)(F)F)(O)C(F)(F)F)=N4)=N2

Molecular Formula

C21H14F8N6O2

Molecular Weight

534.36

References & Citations

[1]Daniel P Zimmer, et al. Abstract 16938: IW-1973 is a Potent Soluble Guanylate Cyclase Stimulator in vitro and in vivo With Extensive Tissue Distribution.|[2]Liu G, et al. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. Am J Physiol Renal Physiol. 2020 Oct 1;319 (4) :F697-F711.|[3]Shea CM, et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Am J Physiol Renal Physiol. 2020 Jan 1;318 (1) :F148-F159.